logo-loader

ANGLE PLC's Andrew Newland on 'very exciting' liquid biopsy breakthrough

Published: 12:52 15 Jun 2017 BST

Andrew Newland, chief executive of ANGLE PLC (LON:AGL,OTCQX:ANPCY) tells Proactive their Parsortix system, which is used to harvest circulating tumour cells from the blood stream associated with cancer, has helped researchers from the Queen Mary University of London's Barts Cancer Institute find two rare cells.

The study of 40 people found that combining them enabled the identification of patients who are 10-times more likely to die of prostate cancer in the short-term.

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24